Cardiovascular Disease Dyslipidemia: Non-Pharmacologic Treatment
نویسنده
چکیده
INTRODUCTION Cardiovascular disease (CVD) is the number one cause of morbidity and mortality in the United States, 1 coronary heart disease (CHD) and myocardial infarction being the leading causes of death. 1 The five major risk factors for CHD – hypertension, dyslipidemia, diabetes mellitus, smoking, and obesity – account for 80% of the risk for CHD. 1,2 Interventions, both pharmacologic and nonpharmacologic, can improve all of these risk factors and decrease the incidence of CVD and its consequences, such as myocardial infarction, angina, congestive heart failure and stroke. 3-6
منابع مشابه
Nonpharmacologic treatment of dyslipidemia.
Cardiovascular disease is the number one cause of morbidity and mortality in the United States, with coronary heart disease (CHD) and myocardial infarction (MI) being the leading causes of death. The 5 major risk factors for CHD—hypertension, dyslipidemia, diabetes mellitus, smoking and obesity—account for 80% of the risk for CHD. Interventions, both pharmacologic and nonpharmacologic, can impr...
متن کاملParaoxonase role in dyslipidemia in thyroid disease (review article)
Introduction: Thyroid disease e.g. hypothyroidism, hyperthyroidism, and subclinical hypothyroidism are among the most common endocrine disorders. Dyslipidemia is prevalent in thyroid diseases and lipid oxidation due to oxidative stress play an important role in the pathogenesis of thyroid diseases. Antioxidant enzymes such as paraxonase have a protective role in these patients and their activit...
متن کاملNutraceuticals in Hyperlipidemic Children: a Systematic Review and Meta-analysis
Background Dyslipidemia is a major risk for cardiovascular diseases. The aim of this study is to review the effects of nutraceuticals to modify lipid disorders in children. Materials and Methods The literature research was conducted in EMBASE, Medline, PubMed, Scopus, ISI Web of Science, and Cochrane library from 2002 until January 2015. The following keywords were used: dyslipidemia, hyperlipi...
متن کاملFenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/recommendations on the importance of LDL lowering with statin treatment. There is also substantial evidence on a number of lipoprotei...
متن کاملAn intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria.
I n t e r v e n t i o n 80 patients were allocated to intensive treatment involving strict treatment goals with a stepwise implementation of behavior modification (diet plan, exercise, and smoking cessation) and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, microalbuminuria, and secondary prevention of cardiovascular disease with aspirin. 80 patients were alloca...
متن کامل